These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 27252317)

  • 41. Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm.
    Cuadrado A; Llerena S; Cobo C; Pallás JR; Mateo M; Cabezas J; Fortea JI; Alvarez S; Pellón R; Crespo J; Echevarría S; Ayesa R; Setién E; Lopez-Hoyos M; Crespo-Facorro B; Agüero J; Chueca N; Garcia F; Calleja JL; Crespo J
    Am J Gastroenterol; 2018 Nov; 113(11):1639-1648. PubMed ID: 29946175
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Standard diagnostic and therapeutic approach to chronic hepatitis C virus (HCV) infection 22 - guidelines].
    Urbánek P; Husa P; Plíšek S; RoŽnovský L
    Klin Mikrobiol Infekc Lek; 2017 Mar; 23(1):22-40. PubMed ID: 28467593
    [No Abstract]   [Full Text] [Related]  

  • 43. Summaries for patients. Treatment for hepatitis C virus infection among inmates.
    Ann Intern Med; 2003 Feb; 138(3):I-50. PubMed ID: 12558381
    [No Abstract]   [Full Text] [Related]  

  • 44. Hepatitis C treatment as prevention in the prison setting: Assessments of acceptability of treatment scale up efforts by prison correctional and health personnel.
    Lafferty L; Rance J; Dore GJ; Grebely J; Lloyd AR; Treloar C;
    Int J Drug Policy; 2021 Dec; 98():103379. PubMed ID: 34311138
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Demonstration of Near-Elimination of Hepatitis C Virus Among a Prison Population: The Lotus Glen Correctional Centre Hepatitis C Treatment Project.
    Bartlett SR; Fox P; Cabatingan H; Jaros A; Gorton C; Lewis R; Priscott E; Dore GJ; Russell DB
    Clin Infect Dis; 2018 Jul; 67(3):460-463. PubMed ID: 29538639
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Route of infection, liver histology and response to interferon in patients with chronic hepatitis caused by genotype 4 HCV infection in a Western country.
    Remy AJ; Verdier E; Perney P; Ducos J; Blanc P; Blanc F; Larrey D
    J Hepatol; 1998 Jul; 29(1):169. PubMed ID: 9696506
    [No Abstract]   [Full Text] [Related]  

  • 47. Treatment effectiveness and side effects of patients with hepatitis C in the prisons of Southern Taiwan: a real-life retrospective analysis.
    Tsai YC; Yu ML; Ko CY; Hsin YH; Tsai QZ; Huang CW
    BMJ Open; 2023 Jun; 13(6):e070490. PubMed ID: 37286314
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current Treatment Options in Patients with Hepatitis C Virus Genotype 6.
    Nguyen NH; Nguyen MH
    Gastroenterol Clin North Am; 2015 Dec; 44(4):871-81. PubMed ID: 26600225
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison.
    Chen CT; Lu MY; Hsieh MH; Tsai PC; Hsieh TY; Yeh ML; Huang CI; Tsai YS; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Huang CF; Huang JF; Dai CY; Chuang WL; Shih YL; Yu ML
    World J Gastroenterol; 2022 Jan; 28(2):263-274. PubMed ID: 35110949
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens.
    El Kassas M; Alboraie M; Omran D; Salaheldin M; Wifi MN; ElBadry M; El Tahan A; Ezzat S; Moaz E; Farid AM; Omar H; Abouelkhair M; Afify S; Elsaeed K; Shazly Y; Doss W; Esmat G
    Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1265-1272. PubMed ID: 29757684
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C.
    Bate JP; Colman AJ; Frost PJ; Shaw DR; Harley HA
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1276-80. PubMed ID: 20594255
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multicenter study on the discontinuation and efficacy of chronic hepatitis C treatment in the Spanish penitentiary population (EPIBAND study).
    Juan Jd; de la Hoya PS; Marco A; Antón JJ; Faraco I; Yllobre C; Pozo E; Hoyos C
    Eur J Gastroenterol Hepatol; 2014 Oct; 26(10):1083-9. PubMed ID: 25076064
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is it possible to eliminate hepatitis C from the prisons of Catalonia, Spain, in 2021?
    Marco A; Guerrero RA; Turu E; Gallego C; Teixidó N; Sastre A; Caylà JA;
    Rev Esp Sanid Penit; 2019; 21(1):38-41. PubMed ID: 31498858
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.
    Selvapatt N; Habibi MS; Brown A
    J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248
    [TBL] [Abstract][Full Text] [Related]  

  • 55. "You need a designated officer" - Recommendations from correctional and justice health personnel for scaling up hepatitis C treatment-as-prevention in the prison setting.
    Lafferty L; Rance J; Byrne M; Milat A; Dore GJ; Grebely J; Lloyd AR; Treloar C;
    Int J Drug Policy; 2022 Aug; 106():103746. PubMed ID: 35636069
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Audit of state-funded antiviral treatment for chronic hepatitis C in Qatar.
    John AK; Al KS; John A; Singh R; Derbala M
    East Mediterr Health J; 2010 Nov; 16(11):1121-7. PubMed ID: 21218734
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epidemiology and treatment of hepatitis C genotypes 5 and 6.
    Al Naamani K; Al Sinani S; Deschênes M
    Can J Gastroenterol; 2013 Jan; 27(1):e8-12. PubMed ID: 23378985
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reassessment of genotype 1 hepatitis C virus subtype misclassification by LiPA 2.0: implications for direct-acting antiviral treatment.
    Guelfo JR; Macias J; Neukam K; Di Lello FA; Mira JA; Merchante N; Mancebo M; Nuñez-Torres R; Pineda JA; Real LM
    J Clin Microbiol; 2014 Nov; 52(11):4027-9. PubMed ID: 25143567
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries.
    Bielen R; Stumo SR; Halford R; Werling K; Reic T; Stöver H; Robaeys G; Lazarus JV
    Harm Reduct J; 2018 May; 15(1):25. PubMed ID: 29751763
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Family Practitioner-Directed Hepatitis C Therapy With Direct-Acting Antivirals Achieves High-Sustained Virologic Response in Prison Population.
    Mokkarala S; Johnson C; Sarkar S; Rudas RJ
    J Correct Health Care; 2019 Apr; 25(2):134-142. PubMed ID: 30866706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.